Multiple Myeloma is a cancer characterized by the proliferation of a clone of plasma cells in the bone marrow and induces overproduction of immunoglobulins (antibody proteins) that crowd out the normal blood-forming cells and prevent them from functioning effectively.

The symptoms of Multiple Myeloma include bone lesions, anaemia, kidney damage and susceptibility to infections. Patients commonly experience bone pain and fractures, also experiencing weight loss, tiredness and repeated infections(2).

The tumor plasma cell clone proliferation induces high level concentration of Monoclonal protein (also called M-Protein) which is the best tumor markers of the disease.

most common Blood Cancer.
In 20%
of cases, the disease develops without symptoms.


Serum and urine protein electrophoresis and their immunological characterization are the gold standard for Multiple Myeloma diagnosis, for monitoring the disease and to assess the patient’s response to treatment.

Protein electrophoresis is recommended by IMWG (International Myeloma Working Group) for screening serum and urine samples for protein abnormality detection(3).

Once the Monoclonal protein is identified (or suspected), it must be characterized by an immunofixation or immunotyping test to identify the M-Protein type (IgG, IgA, IgM, IgD, IgE) and light chain (kappa or Lambda) involved.

Sebia's Expertise

Sebia is the world leader in diagnosis and monitoring of Multiple Myeloma patients by offering a full range of solutions to enable clinicians to provide optimal medical care. Ensuring high quality results adapted to all laboratory sizes. Sebia solutions offer serum and urine proteins electrophoresis (SPE/UPE) for screening and identification (immunofixation/Immunotyping) and follow-up monoclonal antibody therapy with HYDRASHIFT portfolio.